trending Market Intelligence /marketintelligence/en/news-insights/trending/geigfv72e1cvnusp30g5jw2 content esgSubNav
In This List

RepliCel appoints veteran CFO Simon Ma

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


RepliCel appoints veteran CFO Simon Ma

RepliCel Life Sciences Inc. has appointed as CFO Simon Ma, who serves in that position for a number of other public companies.

Ma has been the company's director of finance since June 2016 and would replace Tom Kordyback, who resigned as the company's CFO. Ma is also CFO of various public companies listed on the TSX Venture Exchange or the Canadian Securities Exchange.

Vancouver, British Columbia-based RepliCel Life Sciences is a regenerative-medicine company that develops autologous cell therapies that treat functional cellular deficits.